Actively Recruiting
F-Tryptophan PET/CT in Human Cancers
Led by Barbara Ann Karmanos Cancer Institute · Updated on 2026-01-23
24
Participants Needed
1
Research Sites
274 weeks
Total Duration
On this page
Sponsors
B
Barbara Ann Karmanos Cancer Institute
Lead Sponsor
W
Washington University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
CONDITIONS
Official Title
F-Tryptophan PET/CT in Human Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older.
- Tumor lesion is at least 1 cm in diameter as shown by clinical imaging.
- Ability to lie still in the PET/CT scanner for at least 70 minutes during scanning.
- Women of childbearing potential must not be pregnant or breastfeeding.
- Recent anatomic imaging showing visible tumor for comparison with PET/CT.
- Physical exam within 28 days and blood tests including CBC and multiphasic metabolic panel within 14 days before PET imaging.
- Signed informed consent acknowledging the investigational nature of the study.
- For intracranial tumors: clinical and MRI diagnosis of brain tumor lesions including gliomas or metastatic brain tumors.
- For extracranial neuroendocrine tumors: histologically confirmed well-differentiated metastatic neuroendocrine tumor and ECOG performance status of 2 or better.
- Patients on stable-dose somatostatin analogs for over 3 months may enroll.
- For extracranial breast tumors: clinical and radiological diagnosis of breast cancer and ECOG performance status of 2 or better.
- For rectal tumors: histologically confirmed colorectal cancer located in the rectum and ECOG performance status of 2 or better.
You will not qualify if you...
- Pregnancy or lactation.
- For intracranial tumors: severe increased intracranial pressure, status epilepticus, or symptoms requiring urgent intervention.
- Tumor surgery or radiation within 1 month prior to the PET scan.
- For extracranial neuroendocrine tumors: tumor-directed therapy within 3 months to planned imaging area.
- Ongoing treatment with targeted agents or cytotoxic chemotherapy.
- Use of telotristat ethyl within one month.
- For extracranial breast tumors: tumor resection or radio-chemotherapy within 1 month.
- For rectal tumors: active inflammatory bowel disease involving the rectum such as Crohn's disease or ulcerative colitis.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
Research Team
C
Csaba Juhasz, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here